News
NKTX
3.030
0.00%
0.000
Weekly Report: what happened at NKTX last week (0511-0515)?
Weekly Report · 5d ago
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m
Simply Wall St · 05/15 11:13
Nkarta (NKTX) Gets a Buy from Stifel Nicolaus
TipRanks · 05/13 15:15
Nkarta Price Target Maintained With a $11.00/Share by Needham
Dow Jones · 05/13 10:55
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), PROCEPT BioRobotics (PRCT) and Lineage Therap (LCTX)
TipRanks · 05/13 10:50
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Benzinga · 05/13 10:45
Nkarta Buy Rating Reaffirmed as NKX019 Autoimmune Trials Advance; $16 Price Target Maintained
TipRanks · 05/13 10:19
Nkarta reports Q1 EPS (37c), consensus (37c)
TipRanks · 05/12 22:15
Nkarta GAAP EPS of -$0.37 in-line
Seeking Alpha · 05/12 20:35
Nkarta Q1 EPS $(0.37), Inline
Benzinga · 05/12 20:33
Nkarta Q1 net loss narrows; cash seen funding to 2029
Reuters · 05/12 20:11
*Nkarta: Cash Balance of $266.7 M, Including Cash, Cash Equivalents and Investments, Expected to Fund Ops Into 2029 >NKTX
Dow Jones · 05/12 20:10
Nkarta Q1 FY26 net loss narrows to $27.8 million; G&A expenses drop to $5.9 million
PUBT · 05/12 20:02
BRIEF-Nkarta Q1 EPS USD -0.37
Reuters · 05/12 20:01
NKARTA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS
Reuters · 05/12 20:01
*Nkarta 1Q Loss/Shr 37c >NKTX
Dow Jones · 05/12 20:01
*Nkarta 1Q Loss $27.8M >NKTX
Dow Jones · 05/12 20:01
Weekly Report: what happened at NKTX last week (0504-0508)?
Weekly Report · 05/11 10:27
Weekly Report: what happened at NKTX last week (0427-0501)?
Weekly Report · 05/04 10:24
Weekly Report: what happened at NKTX last week (0420-0424)?
Weekly Report · 04/27 10:28
More
Webull provides a variety of real-time NKTX stock news. You can receive the latest news about Nkarta, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.